ChinaDrugStatus

Sapropterin dihydrochloride

盐酸沙丙蝶呤
Brand: 海普益·Rare Disease / Metabolic·Last verified 2026-11-20

Oral BH4 therapy transitioning from the 2025 Commercial List (#2) into the 2026 NRDL Negotiated List (#42) with a published payment standard of ¥62.00 per 100mg tablet.

China Approval (NMPA)

Approved
Approval Number(s)
国药准字H20233796
Initial Approval Date
Jun 29, 2023
Notice Published
Jun 29, 2023
MAH
Shandong New Time Pharmaceutical Co., Ltd. (山东新时代药业有限公司)
Approved Scope
Treatment of hyperphenylalaninemia (HPA) due to tetrahydrobiopterin (BH4) deficiency in responsive patients (first domestic generic approval).

National Reimbursement

Announced · Effective Jan 1, 2027
2026 Edition Entry
Negotiated #42 · Class B
Agreement Period
2027-01-01 to 2028-12-31
Payment Standard
62.00元(100mg/片)
2026 Payment Scope
Restricted to hyperphenylalaninemia (HPA) due to tetrahydrobiopterin (BH4) deficiency.
限四氢生物蝶呤(BH4)缺乏症所导致的高苯丙氨酸血症(HPA)。

Commercial Insurance List

2025 Only (Not in 2026)

Previously listed in the 2025 Commercial Insurance Innovative Drug List (#2). Graduated into the 2026 Basic NRDL (#42).

Approved Products, Dosage Forms & Approval Numbers

1 verified NMPA record
Approval No.Dosage Form & StrengthEvent & ScopeApproval / Notice DateMAH & Source
国药准字H20233796
Tablet (片剂)
100mg
Initial Approval

Treatment of hyperphenylalaninemia (HPA) due to tetrahydrobiopterin (BH4) deficiency in responsive patients (first domestic generic approval).

适用于对本品治疗有反应的四氢生物蝶呤(BH4)缺乏症所导致的高苯丙氨酸血症(HPA)。

Approved: 2023-06-29
Published: 2023-06-29
Shandong New Time Pharmaceutical Co., Ltd.

Change Timeline

  1. (2027-01-01)Basic NRDL· Catalog published: Nov 14, 2026

    2026 NRDL · Added to Negotiated List

    Newly added to 2026 NRDL Negotiated List (#42, Class B, ¥62.00 per 100mg tablet) for BH4-deficiency HPA; transitioned from the 2025 Commercial List (#2).

    Chinese original: 由2025版商保创新药目录(第2项)转入2026版基本医保谈判药品第42项(乙类,62.00元/100mg片),限BH4缺乏症所致HPA。

    NHSA · PDF p.120Verified 2026-11-20
  2. (2026-01-01)Commercial List· Catalog published: Dec 7, 2025

    2025 Commercial List · Removed in 2026 Edition (#2)

    Listed in 2025 Commercial List (#2) for BH4-responsive HPA; graduated into the 2026 basic NRDL Negotiated List (#42).

    Chinese original: 适用于对本品治疗有反应的四氢生物蝶呤(BH4)缺乏症所导致的高苯丙氨酸血症(HPA),可用于成人及4岁以上儿童。

    NHSA · PDF p.2Verified 2026-11-20
  3. (2023-06-29)NMPA Approval

    NMPA Initial Marketing Approval (国药准字H20233796 · 100mg)

    Treatment of hyperphenylalaninemia (HPA) due to tetrahydrobiopterin (BH4) deficiency in responsive patients (first domestic generic approval).

    Chinese original: 适用于对本品治疗有反应的四氢生物蝶呤(BH4)缺乏症所导致的高苯丙氨酸血症(HPA)。

Verified Names & Aliases

Every English INN, Chinese generic name, brand name, and R&D code is recorded with its source.

盐酸沙丙蝶呤片dosage name(NHSA)
海普益brand zh(NHSA)

Primary Sources for This Record